HIV-2-TAR: 283900 M -1 cm -1 ; A-Site: 270600 M -1 cm -1 ; RRE-IIB: 322900 M -1 cm -1
Ligands: Aminoglycoside and known RNA binding small molecule ligands were purchased from commercial suppliers and used without further purification. Amiloride derivatives were synthesized in-house. 1 Small molecule stock solutions (50 mM) were prepared by dissolving them in either water or DMSO and diluted to appropriate stock concentrations in the assay buffer containing 15% DMSO. Table S1 ). RNA stock solutions were serially diluted in assay buffer from 0 -1 µM concentrations. The Tat peptide solution (10 µL) and RNA solution (10 µL) were combined in a Corning™ low volume round-bottom black 384 well-plates, shaken on a platform stirrer for 5 min, centrifuged at 4000 rpm for 1 min, and allowed to incubate for 30 min (Final Tat concentration = 50 nM, final RNA concentrations = 0 -500 nM). The 384 well-plates were then read on Spectramax-i3™ (Molecular Devices), or
Clariostar™ monochromator (BMG Labtech) microplate readers using the excitation and emission wavelengths of 485 nm (FAM) and 590 nm (TAMRA) respectively. The fluorescence intensities at each RNA concentrations were normalized to the Tat-only control wells. Dissociation constants (Kd) were calculated by fitting the observed relative fluorescence intensity values at each concentration to equation (1) using the GraphPad
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Prism curve fitting software. Assays were minimally conducted in triplicate and each replicate contained three technical replicates. Binding Curves for all results listed in Table S1 i. 50 mM Tris, 10 mM KCl, 0.01% Triton-X-100, pH = 7.4
ii. 50 mM Tris, 20 mM KCl, 0.01% Triton-X-100, pH = 7. 
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iii. 50 mM Tris, 50 mM KCl, 0.5 mM MgCl2, 0.01% Triton-X-100, pH = 7.4
iv. 50 mM Tris, 50 mM KCl, 1.0 mM MgCl2, 0.01% Triton-X-100, pH = 7. 
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v. 50 mM Tris, 50 mM KCl, 4 mM MgCl2, 0.01% Triton-X-100, pH = 7.4
vi. 10 mM NaH2PO4, 25 mM NaCl, 4mM MgCl2, 0.5 mM EDTA, 0.01% Triton-X-100, pH = 7. 
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vii. 10 mM NaH2PO4, 25 mM NaCl, 0 mM MgCl2, 0.5 mM EDTA, 0.01% Triton-X-100, pH = 7.4 viii. PBS: 10 mM NaH2PO4, 1.8 mM KH2PO4, 137 mM NaCl, 2.7 mM KCl, 0.01% Triton-X-100, pH = 7. 
S8
Tat peptide displacement based screening of small molecule libraries: Screening assays were performed in a 50 mM Tris buffer containing 50 mM KCl, 5% DMSO, and 0.01% v/v of Triton-X-100 at pH of 7. was shaken on a platform stirrer for 5 min, centrifuged at 4000 rpm for 1 min, and allowed to incubate in dark for 30 min and read using the excitation and emission wavelengths of 485 nm (FAM) and 590 nm (TAMRA)
respectively. % Displacement of Tat peptide from RNA was calculated using the equation (2). Each screening experiment was performed in triplicate and each replicate contains a technical triplicate.
Molecules that show >25% FID at both tested concentrations of 10 µM, or 50 µM were labeled as hits of the screening assay.
Fraction of Tat Bound to RNA (Fb0):
Total fraction of the Tat peptide bound as a function of the binding constant of each RNA was calculated using reported methods. Tat peptide displacement assay for small molecule hits: Displacement assays to measure the activity of small molecule against each RNA studied in the same 50 mM Tris buffer containing 50 mM KCl, 5% DMSO, and 0.01% Triton-X-100 at pH 7.4. RNA and Tat peptide concentrations used are same as the screening assay. Small molecules were diluted in the assay buffer to achieve final assay concentrations between 0-334 µM. Tat peptide (6 µL), RNA (6 µL), and small molecule solution (6 µL) were combined in a 384 well-plate, shaken on a platform stirrer for 5 min, centrifuged at 4000 rpm for 1 min, and allowed to incubate for 30 min before being read using the excitation and emission wavelengths of 485 nm (FAM) and 590 nm ( Loading Plots:
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